Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …

In 1971, Folkman proposed that tumors could be limited to very small sizes by blocking
angiogenesis. Angiogenesis is the generation of new blood vessels from pre-existing …

Abstract Background/Aim Atezolizumab plus bevacizumab (Atez/Bev) treatment is
recommended for unresechepatocellular carcinoma (u‐HCC) patients classified as Child …

Importance Administration of atezolizumab could be immunogenic and induce undesirable
antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions …

Background & Aims We elucidated the clinical and immunologic implications of serum IL-6
levels in patients with unresectable hepatocellular carcinoma (HCC) treated with …

Background Since atezolizumab plus bevacizumab (ATE+ BEV) regimen for patients with
unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data …

Background and aims The efficacy and safety of systemic atezolizumab and bevacizumab
(atezo/bev) in treatment of patients with unresectable hepatocellular carcinoma (HCC) have …

Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment
for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the …

Simple Summary The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is now
a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only …